Stay updated with breaking news from Agepha Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.
Check out this week’s medical marketing news, people on the move and industry chatter.
Several new drugs have appeared on the scene, and a long-familiar anti-inflammatory splashed into the cardiology space.
Major regulatory news and RCTs topped the list, but COVID-19 and the opioid pandemic had an impact, as did a UK TAVI furor.
While promising, the technology has much to prove, including how much it really adds to standard risk prediction.